Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

The Lancet

Volumn 388, Issue 10042, 2016, Pages 343-355

  Bijlsma, Johannes W J ^a   Welsing, Paco M J ^a   Woodworth, Thasia G ^b   Middelink, Leonie M ^c   Pethö Schramm, Attila ^d   Bernasconi, Corrado ^d   Borm, Michelle E A ^e   Wortel, Cornelis H ^f   ter Borg, Evert Jan ^g   Jahangier, Z Nazira ^h   van der Laan, Willemijn H ⁱ   Bruyn, George A W ^j   Baudoin, Paul ^j   Wijngaarden, Siska ^k   Vos, Petra A J M ^l   Bos, Reinhard ^m   Starmans, Mirian J F ⁿ   Griep, Eduard N ^g   Griep Wentink, Joanna R M ^g   Allaart, Cornelia F ^o   Heurkens, Anton H M ^p   Teitsma, Xavier M ^a   Tekstra, Janneke ^a   Marijnissen, Anne Carien A ^a   Lafeber, Floris P J ^a   Jacobs, Johannes W G ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Middelinc   (Netherlands)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Roche Netherlands BV   (Netherlands)

^f Accelovance   (United States)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h TERGOOI HOSPITAL   (Netherlands)

ⁱ Sint Maartenskliniek Woerden   (Netherlands)

^j MC Groep   (Netherlands)

^k GELRE HOSPITALS   (Netherlands)

^l AMPHIA HOSPITAL   (Netherlands)

^m MEDICAL CENTER LEEUWARDEN   (Netherlands)

ⁿ Sittard Geleen Heerlen   (Netherlands)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p MEANDER MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DAS28; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973539391     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30363-4     Document Type: Article

References (50)

1. 1 Smolen, JS, Landewé, R, Breedveld, FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
2. 2 Rantalaiho, V, Korpela, M, Laasonen, L, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther, 12, 2010, R122.
3. 3 van Nies, JA, Tsonaka, R, Gaujoux-Viala, C, Fautrel, B, van der Helm-van Mil, AH, Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74 (2015), 806–812.
4. 4 Singh, JA, Saag, KG, Bridges, SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (2016), 1–26.
5. 5 Buckley, F, Finckh, A, Huizinga, TW, Dejonckheere, F, Jansen, JP, Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21 (2015), 409–423.
6. 6 van der Heijde, D, Klareskog, L, Rodriguez-Valverde, V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54 (2006), 1063–1074.
7. 7 Breedveld, FC, Weisman, MH, Kavanaugh, AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006), 26–37.
8. 8 Weinblatt, ME, Kremer, J, Cush, J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res 65 (2013), 362–371.
9. 9 Gabay, C, Emery, P, van, VR, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
10. 10 Smolen, JS, Beaulieu, A, Rubbert-Roth, A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008), 987–997.
11. 11 Singh, JA, Beg, S, Lopez-Olivo, MA, Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 38 (2011), 10–20.
12. 12 Arnett, FC, Edworthy, SM, Bloch, DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.
13. 13 Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
14. 14 Anderson, JK, Zimmerman, L, Caplan, L, Michaud, K, Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res 63:suppl 11 (2011), S14–S36.
15. 15 Jacobs, JW, Ten Cate, DF, van Laar, JM, Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice. Rheumatology 54 (2015), 959–961.
16. 16 Choy, EH, Smith, C, Dore, CJ, Scott, DL, A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44 (2005), 1414–1421.
17. 17 Aletaha, D, Ward, MM, Machold, KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52 (2005), 2625–2636.
18. 18 Boers, M, Jacobs, JW, van Vliet Vlieland, TP, van Riel, PL, Consensus Dutch health assessment questionnaire. Ann Rheum Dis 66 (2007), 132–133.
19. 19 Bruynesteyn, K, van der Heijde, D, Boers, M, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol 29 (2002), 2306–2312.
20. 20 van der Heijde, D, How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26 (1999), 743–745.
21. 21 Felson, DT, Anderson, JJ, Lange, ML, Wells, G, LaValley, MP, Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis Rheum 41 (1998), 1564–1570.
22. 22 Pope, JE, Khanna, D, Norrie, D, Ouimet, JM, The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 36 (2009), 254–259.
23. 23 Maini, RN, Taylor, PC, Szechinski, J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006), 2817–2829.
24. 24 Verstappen, SM, Jacobs, JW, van der Veen, MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007), 1443–1449.
25. 25 Campbell, L, Chen, C, Bhagat, SS, Parker, RA, Ostor, AJ, Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50 (2011), 552–562.
26. 26 Genovese, MC, Rubbert-Roth, A, Smolen, JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 40 (2013), 768–780.
27. 27 Albert, DA, Are all biologics the same? Optimal treatment strategies for patients with early rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. J Clin Rheumatol 21 (2015), 398–404.
28. 28 Nam, JL, Villeneuve, E, Hensor, EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 73 (2014), 1027–1036.
29. 29 Smolen, JS, Emery, P, Fleischmann, R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383 (2014), 321–332.
30. 30 Yamanaka, H, Ishiguro, N, Takeuchi, T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology 53 (2014), 904–913.
31. 31 Emery, P, Burmester, GR, Bykerk, VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74 (2015), 19–26.
32. 32 Atsumi, T, Yamamoto, K, Takeuchi, T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75 (2016), 75–83.
33. 33 Burmester, GR, Rigby, WF, van Vollenhoven, RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2015-207628 published online Oct 28.
34. 34 Detert, J, Bastian, H, Listing, J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72 (2013), 844–850.
35. 35 Moreland, LW, O'Dell, JR, Paulus, HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64 (2012), 2824–2835.
36. 36 Quinn, MA, Conaghan, PG, O'Connor, PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005), 27–35.
37. 37 Nam, JL, Villeneuve, E, Hensor, EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73 (2014), 75–85.
38. 38 Horslev-Petersen, K, Hetland, ML, Junker, P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73 (2014), 654–661.
39. 39 Calasan, MB, van den Bosch, OF, Creemers, MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther, 15, 2013, R217.
40. 40 O'Dell, JR, Curtis, JR, Mikuls, TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 65 (2013), 1985–1994.
41. 41 van Vollenhoven, RF, Geborek, P, Forslind, K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379 (2012), 1712–1720.
42. 42 Leirisalo-Repo, M, Kautiainen, H, Laasonen, L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 72 (2013), 851–857.
43. 43 Bergman, GJ, Hochberg, MC, Boers, M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39 (2010), 425–441.
44. 44 Salliot, C, Finckh, A, Katchamart, W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70 (2011), 266–271.
45. 45 Baillet, A, Gossec, L, Paternotte, S, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res 67 (2015), 905–912.
46. 46 Gaujoux-Viala, C, Mouterde, G, Baillet, A, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 79 (2012), 149–155.
47. 47 Isaacs, JD, Harari, O, Kobold, U, Lee, JS, Bernasconi, C, Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R204.
48. 48 Straub, RH, Cutolo, M, Pacifici, R, Evolutionary medicine and bone loss in chronic inflammatory diseases–a theory of inflammation-related osteopenia. Semin Arthritis Rheum 45 (2015), 220–228.
49. 49 Innala, L, Moller, B, Ljung, L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther, 13, 2011, R131.
50. 50 Ridker, PM, From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118 (2016), 145–156.